Hypertrophic Cardiomyopathy Association (HCMA) is a leading organization dedicated to improving the lives of individuals with hypertrophic cardiomyopathy (HCM) and advancing global understanding of the disease. Founded in 1996, HCMA provides clinically reviewed information, support options, and member services to expand knowledge about HCM and address important issues within the community. With a commitment to support, education, advocacy, and research, HCMA strives to prevent untimely deaths and enhance care for individuals with HCM, regardless of gender, ethnicity, age, or geographic location.
Tenaya Therapeutics is a pioneering company that focuses on investigational therapies for various genetic disorders, including hypertrophic cardiomyopathy (HCM). Their groundbreaking TN-201 gene therapy for HCM has shown promising results, with the first person receiving a dose. Tenaya Therapeutics is at the forefront of future therapy options, including genetic therapy trials and investigational medications, aiming to provide innovative solutions for individuals with HCM.
Generated from the website